Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

Background All randomised phase 3 studies of selective internal radiation therapy for
advanced hepatocellular carcinoma published to date have reported negative results …

Immunotherapy has become an established pillar of cancer treatment improving the
prognosis of many patients with a broad variety of hematological and solid malignancies …

Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight
into this therapy resistance is still lacking. Here we generate a humanized (Hu)-mouse …

With the burgeoning use of immune-based treatments for cancer, never has there been a
greater need to understand the tumour microenvironment within which immune cells …

Highlights•A melanoma consensus conference, organised by the ESMO Guidelines
Committee, was attended by 32 experts from 14 countries•The experts compiled …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Patients with cancer with liver metastasis demonstrate significantly worse outcomes than
those without liver metastasis when treated with anti–PD-1 immunotherapy. The mechanism …

Cancer immunotherapy has revolutionized the treatment landscape in medical oncology, but
its efficacy has been variable across patients. Biomarkers to predict such differential …